Illinois Mandates Medicaid Coverage for Preterm Birth Blood Tests, Benefiting Sera Prognostics
SERA sits 18% above its 52-week low of $1.56.
Summary
Illinois has passed legislation requiring its Medicaid program to cover proteomic blood tests for identifying and managing preterm birth risk. This is a significant positive development for Sera Prognostics, as its PreTRM® Test is currently the only broadly validated, commercially available blood-based test of its kind. The news follows Sera's Q1 2026 report of a 63% revenue decline and increased net losses. With Illinois having approximately 50,000 Medicaid births annually, this mandate opens a substantial new market for Sera's product, offering a crucial revenue opportunity for the financially challenged company. Investors should watch for further details on implementation timing and and specific coverage parameters.
At the time of this announcement, SERA was trading at $1.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.1M. The 52-week trading range was $1.56 to $4.09. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.